sabcs 2022: results of the randomized, multi-dose phase 2 serena-2 trial
Published 1 year ago • 266 plays • Length 17:10Download video MP4
Download video MP3
Similar videos
-
16:12
sabcs 2022: overall survival analysis of the randomized stic ctc trial
-
12:19
sabcs 2022: updated survival results of the randomized, phase 3 study destiny-breast03 q & a
-
11:35
sabcs 2022: primary results of the randomized, phase 3 study destiny-breast02 q & a
-
4:06
serena-2: camizestrant vs fulvestrant in post-menopausal women with advanced er /her- breast cancer
-
14:18
sabcs 2022: primary results from the positive trial (ibcsg 48-14 / big 8-13)
-
6:55
mafalda oliveira, sabcs 2022: camizestrant vs fulvestrant for advanced er her2- breast cancer
-
4:08
sabcs 2022 highlights
-
8:49
sabcs 2022: results from the phase iii capitello-291 trial
-
20:17
sabcs snippets: after asco 2024
-
16:10
emerald study lead to the elacestrant fda approval - oncbrothers in discussion w/ dr. aditya bardia
-
11:45
sabcs snippets: keynote-522 phase 3 results
-
1:17
key trial updates in serds in er /her2- breast cancer from sabcs 2022
-
0:51
sabcs 2022: key highlights
-
2:57
key data from the san antonio breast cancer symposium (sabcs) 2022
-
0:52
best of sabcs 2022 news - adam brufsky, md, phd - promotional video
-
1:25
sabcs 2022: clinical trial highlights
-
1:06
sabcs 2022 highlights
-
0:56
remaining questions on the management of her2-low breast cancer
-
0:52
first-line camizestrant for er /her2- advanced breast cancer
-
0:55
key highlights from sabcs 2022
-
1:51:16
dr. bora lim | challenging types of breast cancer | sabcs 2022 | education session
-
17:10
sabcs 2022: trio-us b-12 talent: neoadjuvant tdx with or without anastrozole for her2-low, hr e...